Kymab Ltd - Product Pipeline Review

Global Markets Direct’s, ‘Kymab Ltd - Product Pipeline Review - 2016’, provides an overview of the Kymab Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kymab Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kymab Ltd

The report provides overview of Kymab Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kymab Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kymab Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kymab Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kymab Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kymab Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Kymab Ltd ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Kymab Ltd Snapshot 6

Kymab Ltd Overview 6

Key Facts 6

Kymab Ltd - Research and Development Overview 7

Key Therapeutic Areas 7

Kymab Ltd - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Kymab Ltd - Pipeline Products Glance 11

Kymab Ltd - Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

Kymab Ltd - Drug Profiles 13

HIV vaccine - Drug Profile 13

Product Description 13

Mechanism Of Action 13

R&D Progress 13

KY-1003 - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

KY-1005 - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

KY-1006 - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

KY-1007 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

KY-1016 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

KY-1034 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

KY-1041 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

KY-1043 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

KY-1044 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

KY-1047 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

KY-1050 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

KY-1051 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

KY-1055 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Vaccines for HIV and Bordetella pertussis Infections - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Kymab Ltd - Pipeline Analysis 29

Kymab Ltd - Pipeline Products by Target 29

Kymab Ltd - Pipeline Products by Molecule Type 30

Kymab Ltd - Pipeline Products by Mechanism of Action 31

Kymab Ltd - Dormant Projects 32

Kymab Ltd - Locations And Subsidiaries 33

Head Office 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

List of Tables

List of Tables

Kymab Ltd, Key Facts 6

Kymab Ltd - Pipeline by Indication, 2016 8

Kymab Ltd - Pipeline by Stage of Development, 2016 ...

List of Tables

Kymab Ltd, Key Facts 6

Kymab Ltd - Pipeline by Indication, 2016 8

Kymab Ltd - Pipeline by Stage of Development, 2016 9

Kymab Ltd - Monotherapy Products in Pipeline, 2016 10

Kymab Ltd - Preclinical, 2016 11

Kymab Ltd - Discovery, 2016 12

Kymab Ltd - Pipeline by Target, 2016 29

Kymab Ltd - Pipeline by Molecule Type, 2016 30

Kymab Ltd - Pipeline Products by Mechanism of Action, 2016 31

Kymab Ltd - Dormant Developmental Projects,2016 32

List of Figures

List of Figures

Kymab Ltd - Pipeline by Indication, 2016 8

Kymab Ltd - Pipeline by Stage of Development, 2016 9

Kymab Ltd - Monotherapy ...

List of Figures

Kymab Ltd - Pipeline by Indication, 2016 8

Kymab Ltd - Pipeline by Stage of Development, 2016 9

Kymab Ltd - Monotherapy Products in Pipeline, 2016 10

Kymab Ltd - Pipeline by Target, 2016 29

Kymab Ltd - Pipeline by Molecule Type, 2016 30

Kymab Ltd - Pipeline Products by Mechanism of Action, 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports